Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMO, it's just Silly Season.
I thought this was a reasonable opinion:
investorshub.advfn.com/boards/read_msg.aspx?message_id=167317795
M$
Since inception of Breathtec /Algernon shareholders have suffered huge losses as Kulwant Malhi has continued to score millions of dollars in profits for himself and shareholders of another company. Kulwant Malhi has publicly sullied Moreau and Williams by making them get their hands dirty by creating a ridiculous conflict of interest. Moreau and Williams went to work for Kulwant Malhi whom at the time was Chairman Of The Board at First Responder Technologies. The fact Malhi ended up with the FAIMS technology all to himself at Cannabix after Algernon shareholders paid for half it's advancements is just one more glaring example that we got robbed by this group of shameless individuals whose combined relationships are like mob family ties. No matter what deals Moreau puts together Malhi is likely in someway benefits. Your claim of bankruptcy being attached to the decision to surrender the FAIMS technology is a bogus one. As we all know the mob family had already cut a deal to buyout the Repurposed Drugs angle and FAIMS was touted as still being a part of the story at Algernon moving forward. Then out of nowhere they unloaded a bogus story about not finding a path to monetize the FAIMS tech. The overall cost to continue it's collaboration with Cannabix was nil. But no, Moron Moreau simply walked away from the FAIMS and pivoted Algernon 100% towards the our in the sky pursuit of COVID-19. 90% of all messaging and money got thrown at COVID-19. It was full steam ahead and FAIMS became an afterthought to shareholders not paying attention to the big picture. We got royally screwed dude. When COVID failed miserably, Moron Moreau told the market who dumped the shares to historic lows that Algernon wasn't a COVID company after an unrelenting campaign to tell the market the exact opposite - that Algernon was in fact a COVID company. Moron Moreau never got a handle on the IPF/Chronic Cough angle to this very day. The market has already been turned of by Moreau's messaging skills. They suck royally! Appease Moreau. Appease King Cobra. Appease the mob family. Appease Appease Appease all you want. It doesn't change the true story and I'm here to continue telling the story that has zero wins and manufactured losses year after year. Algernon Pharmaceuticals and it's mob family mentality leadership is one for the books
M$
Yeah really - for all the reasons I've already laid out. Give it a rest why don't cha.
I have my target numbers and could careless what happens after that. I've been around since B4 inception of Breathtec.
I've already told that story as well. Hold hands all you want to get to whatever pricetag you deem worthy of your time and money.
The time and money I've had twisted up in the HQ circus act can never be adequately returned. Time is money and Moreau has played destructive games with it.
Do you. No point in going around in circles over the FAIMS. The FAIMS & Breath Collector could have sat on the shelf at Algernon just like it's sitting on the shelf at Cannabix.
Instead, Moreau simply gave it all away for not one single dime or favor (shares) from Cannabix/Kulwant Malhi. Instead. Cannabix owns shares of Algernon.
That's the point!
How anyone whose been around long enough can't see that all of Algernon's failures lead to Malhi making out like a bandit remains blind to whatever myths they are holding onto for dear life.
Meanwhile...it's the weekend.
Have a Beer & Have @ it Here.
M$
If anyone out there wants a mind opener this evening - go back to the depiction of Dante's Inferno here:
investorshub.advfn.com/boards/read_msg.aspx?message_id=168341136
Do you see the Devil is frozen from the waste down in a block of ice for all eternity?
Now look at the Devil's head on the right side.
You can clearly see the head of someone else.
It has the spitting image of a pennyland CEO.
You can't make this shit up.
Can you?
TGIF
M$
Oh...just real quik.
What ever happened to your POC FAIMS Breathalyzer for researchers to chase whatever molecules rheir heart desires?
It's sitting over at Cannabix to do whatever they want with it.
This is exactly what Algernon and Cannabix was collaborating on before Moreau came along doing the bidding of Kulwant Mali.
cannabixtechnologies.com/technology/faims-thc-breathalyzer-system/
Simply eliminate the words THC in the naming off the Black|Box. It's just a BS cover. The device is meant to detect far beyond THC.
Ditching the FAIMS was a fireable offense.
Like the failure to remove 45 from power - we/the masses are learning the hard way.
However, someone believes Moreau & Company deserves bonus checks.
TGIF
M$
In comparison to a real world pharmaceutical company that develops its own molecules - Yeah the timeline is different among a slew of other company structure things. However, we are not here to compare Algernon Pharmaceuticals (described as a virtual company by Moreau in last known webcast) to a true pharmaceutical company. You're simply parroting the same angle management has used to make it seem as if Algernon is going to roll out clinical trials in rapid fire succession. They will not. Just like they are currently pushing every single self imposed start of a clinical trail down the road quarter after quarter.
The DMT angle is no different given they 1st planned a Q4 2021 DMT study. Q2 2022 begins next week. Yet, you are being diluted all the same. At what cost is it to you for Algernon to have run ONE STUDY TO COMPLETION IN 3 YEARS TIME? That being the COVID-19 - jump on the bandwagon - last minute - half ass - study thrown together 1st in South Korea then Romania (2nd World Country).
Dude, look at the total cost to your shares since their Repurposed Drugs strategy has gone into effect. How many shares do you have now? How much is your shares worth since you first invested? That's the frigging cost of running Algernon studies on a timeline you believe is advantageous to shareholders. You have been decimated dude. Folks now appear to be delusional (shell shocked) about their past and present standing as a shareholder. Believe me when I tell you I will not forget any of the past and I'm firmly grounded in knowing where I stand as a shareholder of this Hot House penny stock.
Algernon Pharmaceuticals Is A Show Beneath Earth
Let This Guy Be Your Traveling Guide
Someone posted about giving bonuses to management.
You can't make this shit up.
Can you?
TGIF
M$
You continue to go back and forth with your reasoning. Why you continue to address me with those type of ping pong questions suggest you're a glutton for punishment. There is no such grand plan to increase share price before a capital raise.
Sir, the cement has already been poured and your feet are planted in wet concrete. Once the ink is dry on the capital raise and your theories are completely debunked surely it will be some other moronic thing Moreau had done that will become the next reason for concern.
You are actually advocating for bonuses for management? Just friggin WOW! Management handing each other shares as if they have done anything other than decrease shareholder value exponentially is another raw slap in the face.
Yeah, Dr. Williams reads books and throws darts at a list of existing molecules. Moreau runs around pennyland like a peacock with its P Cock cut off screaming about conducting insignificant studies as if they're on the precipice of changing the world of medicine as we know it. We all fell for that straight up Bullsh!t.
Now Moreau states he wants to concentrate on fundamentals. So what was he concentrating on for the past 4 years? Whatever Kulant Malhi told him to concentrate on that Made Malhi Millions - that's what. That's the guy at the helm @ Algernon and his colors have not changed since.
As to my holdings of this junk stock. I've previously stated more than once I am looking for the exit. I'd like to exit at $30 per share usd. However, that seems like a pipe dream at this point with massive dilution on the horizon. Thus, I'm targeting a timeline of the end of Phase 1's. I will not be around for any Phase 2 data readout in 2024 or 2025.
Without a doubt in my mind, this will be my final penny world stock I'll ever throw money at. I'm just beside myself to know of all the penny stocks out there Breathe/Algernon's leadership has been one big snake oil salesman scheme since the beginning. Of the 4 CEO's since 2016 (Malhi, LaTorre, Wong, Moreau) the tag team of Malhi & Moreau is a horror story for the ages.
The next chapter is being written right now. It's titled Miraculins 2.0 with many of the characters from Miraculins decade long downfall now appearing in the new chapter at Algernon. The more shit changes the more it stays the same. One only needs to open their eyes and read it in black and white.
You can't make this shit up. As I've personally spoken to 3 of the 4 CEO's (not LaTorre) and ADAMANTLY pushed to speak to a 5th CEO. I had roundly made it known Moreau should have been removed based on his overall performance which includes his endorsement of the BS IPF/Chronic Cough study in Australia being on a timeline that he's pleased with. At a time when it was critical to get the data in an effort to keep the stock price from falling to historic lows where they remain to date when you factor in the 100 to 1 reverse split.
T G I F
M$
Happy Belated 4th Anniversary To Moreau
www.globenewswire.com/news-release/2018/03/01/1409075/0/en/Breathtec-Biomedical-Announces-Appointment-of-CEO.html
Moreau's managed to inflict a lot of damage to shareholders in the last 4 years and we likely have not seen nothing yet.
If there are positives about Moreau's story at Breathtec Biomedical/Algernon Pharmaceuticals I'd like to hear it.
He's thus far taken shareholders on a wild outlandish demonic ride throughout pennyland before driving the company over the cliff.
Let Dr. KSS (@BioPub) tell it along with Moreau they both basically swore to shareholders Moreau wouldn't do it again.
So what's another 2 3 4 5 6 Fold dilution of shares after the 2 to 1 reverse split then 100 to 1 reverse split mean?
It means forget whatever comes out of their fork tongued mouths and watch what they will actually do.
Their shares are handed to each other while yours are taken away at breakneck speed (100 to 1) heading for yet another cliff at pennyland stock prices.
Other than Moreau is anyone happy about the last 4 years?
M$
Yeah...it looks like you finally nailed it. That's exactly what's going to happen. There will be no pleasant surprises coming from management. There never has been in all of Moreau's tenure. He won't start now. What he's good at is dilution (see Miraculous). That goes for him and his hand picked Chairman and CFO. Moreau's picks of personnel including former CEO of Xortx as an advisor paints a pretty clear picture. Moreau thinks Xortx is doing just swell trading under 2 $ and $ not long ago since their uplist to Nasdaq. Moreau considers that good neighborly company. As in struggle together. Moreau has already telegraphed there will be a struggle ahead. Moreau says positive Phase 2 data readout is needed to approach big pharma for a handout. I don't see a Phase 2 data readout (statistically significant data readout) for any drug in the revamped pipeline until 2024 or even 2025. If there is anyone here that believes a data readout for Phase 2 will happen prior to 2024 do tell. The floor is yours.
M$
Uplist/3 Fold Dilution/Or Just Pumping...Do Tell
IMO, Big News is a partnership that comes with non dilutive financing.
Otherwise, what could it be we don't already know...Do Tell
In all my years posting here I never dangled shit in front of this msg board without an explanation.
Otherwise, I'd likely just shut the f*** up.
From what's currently in view is a financing of 10M US$ around $4 per share.
That adds 2,500,000 Outstanding shares plus 2,500,000 Warrants.
Thus, post financing there will be at minimum 4,200,000 Outstanding Shares plus millions of warrants.
Will Nasdaq increase the Market Cap post the uplist?
My best guess is the stock will still trade in the cash on hand area of $2 $3 per share.
As Moreau uses Xortx as a pure comparison example of an uplist to Nasdaq and it's "softening" of share price thereafter.
M$
Algernon has a Facebook page?
Doesn't appear to be all that important to date.
Maybe this will become important for the long run of they get their heads out of their @sses @ HQ:
www.afternic.com/forsale/algernonpharma.com?utm_source=TDFS&utm_medium=sn_affiliate_click&utm_campaign=TDFS_GoDaddy_DLS&traffic_type=TDFS&traffic_id=GoDaddy_DLS
Experts say 14 characters or less is the ideal number for a website domain. Don't let it become a freewheeling blog address about all things Algernon.
Business 101
M$
55
Yeah 55. Let's all turn this into pure fantasy land. Surely, once the uplist and crushing finance happens it'll be onto something else wild and outlandish as if the clueless episodes never happened.
Oh...I would assume one doesn't necessarily need to sit wit the CEO to establish a communication. Try using email or pick up the phone. It seems like pretty simple stuff - No?
Meanwhile a thousand shares traded here (OTC) or there (CSE) pushes Algernon around like a Ragdoll.
Crazy Ch!t A!nt !t
M$
The super soft sugarcoated version:
I take no pleasure in anyone's belief Algernon has enough money on hand to trip through multiple Phase 1 clinical trials before needing cash.
Please break down the amount of cash on hand and the cost of all clinical trials thus far loosely projected to start in 2022:
DMT Stroke, Small Cell Lung Cancer, Pancreatic Cancer. Chronic Kidney Disease, and whatever other pie in the sky Moreau adds to the cake batter in 2022.
Sir, are you aware of the fact Algernon filed an SEC Form 1 on 2-22-2022? If so. do you understand it was filed to issue new shares on the Nasdaq as soon as possible?
What I suggest anyone still confused about the situation at hand is call Beer Buddy and ask him directly what's up with the SEC filings. Surely, he can further explain the financing plan as written in the filings.
Sir, the facts you dispute are written in a relatively EZ to understand black and white format/font here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167963800
OAN: NJV you get no rebuttal from me.
M$
Ohhh 55. Where should one start?
55
5 Million to 6 Million Outstanding shares. That appears to be clearly what you are suggesting. I'm saying that's 3 to 4 times dilution. Which equates to ANOTHER dilution of pre-consolidated/pre-reverse split shares by 300% to 400%.
In other words - the initial 100 to 1 reverse split will effectively become a 400 to 1 or 500 to 1 reverse split. Sir, the size of the Pizza Pie doesn't change. What changes is the size of your slice. Dilution from here forward is like being left with crust stuffed with bullshit.
There is no sugarcoating of the numbers. They are what they are no matter how you try to get to 5-6 Million shares. It's an insane continuation of dilution that doesn't affect management as they kill us all off. No point in rehashing what I posted yesterday. However, your theories basically forgets the past. Which is something I'll never do.
Bottom line is Moreau is a moron who only knows small-time dealings. He's going to continue running the company into the ground with petty penny private placements. The uplist if approved will prove what independent analysts (not Smackie Mackie Research Uddin) think of Algernon's "Virtual Reality" company as moronically described by Moreau in the latest webcast posted @ Stockhouse.com
If it's anything like what the market thinks about XORTX since it's Nasdaq listing (Pure Comparison) expect the bottom to fall out in short order while nothing but a Phase 1 clinical trial gets underway. More Pain and Anguish is coming sooner rather than later.
Please begin to wrap your mind around the fact ANY dollar amount regarding share price must be divided by 100. That is the actual and factual formula needed to know where you stand in relationship to all of Moron Moreau's Moves Moving Forward.
Someone, Anyone, please tell Beer Buddy I said Hell O.
M$
Deeper Dive N2 XORTX (Moron Moreau's latest "Pure Comparison")
XORTX Pipeline:
XORTX
Ummm...
55
The PROBLEM with both COVID studies is neither one of them were designed to move beyond Phase 2. Meaning, they were just show trials. The same thing goes for the IPF/Chronic Cough study. It's a show trial. The data to run a legitimate Chronic Cough study powered for statistical significance already exists within the preclinical trial data purchased from Nash Pharmaceuticals in the reverse takeover of Breathtec Biomedical (now named Algernon Pharmaceuticals) back in 2018. The history is all there. I'm not here to revise any of it's pure evil and ugliness. The COVID studies took us deep into dilution status. Bottom line is we got fucked by management and they are not done yet.
M$
I Must Admit Trying To Keep Up With Mush Mouth Moreau Is A Task Unto Itself:
Masterful Music
Thanks For Chiming In
en.wikipedia.org/wiki/The_Division_Bell
M$
What do you see?
I see a stock in limbo awaiting Q1 movement towards a clinical trial. Any clinical trial! A clinical trial hasn't been started at Algernon going on 2 years now. All we do is fuckin wait around as the paint dries at Algernon's new HQ location.
I expect the offering will be around $4 per share if they can get it. The same playbook as XORTX.
I also expect the share price will experience what Moreau calls "A Softening" of the share price after the offering
Meaning, 1 $ share price is not out of the realm of possibility. I'm thinking we will see 2 $ again no matter what happens.
Thanks Shell.
Is there anybody else out there?
M$
If this BS stock gets anywhere near the 6M Outstanding Shares as you suggest, the math says you're now Burnt Toast. You're talking about nearly 4X dilution from here + matching warrants. There's barely any meat left on the bone already for pre-split shareholders, but I surmise Moreau's reorganization plan doesn't account for that. Why would it? He, along with the others @ HQ have very little skin in the game. Either way, I'm seeing a very shaky start to 2022. Yet again, the CEO blows smoke up our butts with all his pie in the sky timelines and likely none of them will come to fruition as laid out. Last thing, as the calendar is set for the Phase 1's, I see no path where Algernon will get to a Phase 2 ("Everybody Wants In At Phase 2" - Moreau) data readout before 2H 2024. 2025 if Moreau returns to Australia for any of the clinical trials Moreau can do a lot more damage between now and then in whatever insane way we have yet to encounter. Moreau is a Magician @ messing shit up. Thanks for your opinion. It's good to see someone else is still out there.
Oh, the hiring of the old Chairman Of The Board from XORTX is one to follow. Yeah, XORTX uplifted to Nasdaq but look at it's performance. It's a friggin 1 dollar stock with a BS market cap. That's the type of shit Moreau holds up as being successful. IMO, Moreau is a small time operator. He's never been as far as he's gotten prior to King Cobra appointing him to the job. In all of Moreau's time before Algernon. Moreau raised a total of 30 Million dollars. Moreau now sits in a chair that gives him the opportunity to raise 50 Million dollars and surely he's salivating over how much of that he can get ASAP. With his fire sale track record I don't think for one second he would care about the share price once uplisted, if ever. Just delay delay delay dilute.
peace,
M$
Question To Msg Board:
The 11th Hour
11 Trading Days left until the end of 1st Quarter.
M$
Outro
Having adjusted the potential capital raise to $4 USD per share for $10 Million USD - The projection of Algernon realizing a Market Cap of $33 Million USD per Andre Uddin at Research Capital - Uddins' targeted share price comes to $7.90 USD based on a non statistically significant data readout for Chronic Cough.
The more I dig at Algernon's "Corporate Fact Sheet" the outcome only gets worse for shareholders.
Formula: $7.90 per share x 4,174,868 Outstanding Shares = $33 Million USD.
Thus, in order for me to exit at $30 per share (break even point for many if not most) - Algernon needs to realize a Market Cap of $125 Million USD without any warrants exercised.
It's A High Wire Act Over The Lake Of Fire In A Hailstorm
Anyone with better numbers and/or opinions please share with us.
I'm just 1 person with opinions I don't hold back.
I have zero control over what anyone else posts.
That's left to AGNPF moderators and ultimately ihub admins.
M$
PostScript
Managment has ran face on into real world turmoil. A global pandemic to a potential World War III to market meltdowns and recession on the horizon. With all that headwind coming, why would you still conduct clinical trials outside of North America. IMO, it's crazy and unreasonably uncontrollable. Algernon will be relying on other governments actions to dictate data readout timelines like Australia's countrywide COVID-19 lock down. Moreau loves pawning off faults to entities you can't say or do shit about. Henceforth, knowing what we do know, running tax incentive clinical trials would amount to more cowardly leadership on full display.
Of note:
www.streetwisereports.com/article/2021/12/29/co-looks-to-us-for-help-fighting-strokes.html
At one point in my so-called investment of Algernon (formerly Breathtec Biomedical), I had a targeted share price of $3 USD to exit with my targeted profit amount.
That number changed to a targeted share price of $10 USD upon the 1st reverse split by Moreau.
That number changed to an unrealistic targeted share price of $900 USD upon the 2nd reverse split by Moreau.
From $3 price target to $10 price target to $900 price target.
Those numbers represent the reduction/destruction of shares per reverse splits and subsequent and pending reconstruction/increase of outstanding shares/dilution.
Moreau has mastered the art of screwing you over a barrel - stuffing you inside the barrel - kicking the barrel over Niagara Falls.
Surely, I'm very interested in simply getting to a fire sale $30 USD price target and finally ascending from Purgatory.
Get us to $30 USD Moreau and your ilk will never see another post from me - on any message board - for any of your penny play stocks including those publicly run by the Wizard Of Deception - King Cobra.
A strictly a business word of advice - Management should have secured the AlgernonPharma.com web domain. Everyone knows a 5 character or less domain name is most desirable from a business standpoint. That would appear to be relevant to management by simply looking at Algernon Pharmaceuticals official twitter page:
Algernon Pharmaceuticals@AlgernonPharma
twitter.com/AlgernonPharma?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Algernon needs to revamp its corporate website. It's full of holes and its overall design is underwhelming to say the least. Reach out to a dynamic webpage builder. Take a page from Cybin or even GH Research. GH Research has a very clean and refreshing look. Algernon's website reminds me of AS SEEN ON TV infomercials with added stuff. Moreau’s in a bunch of video’s plastered throughout the website.
Revamping the Corporate website and purchasing the algernonpharma.com domain name would go a long way towards seeking investors seeking information about the company. You should strive to captivate your audience. You can't do that without keeping your website updated. It's good to see Algernon got around to adding a coherent Pipeline outline to the website. The Pipeline is the #1 public information one seeks to get a snapshot of what the hell a pharmaceutical company is tinkering with under the hood. The website is supposed to be a Window For The World to make a quick and reasonable assessment of what the hell Algernon has going for itself.
Is there no one in the family/friends plan Algernon can hire (tech geek) to meet the web page challenges of a company pursuing Psychedelics? You do know Psychedelic investors are like cult following pot Stock investors. They like VISUALS. They always opine a lot about their past and present use of drugs. Design a website that can draw in rabid psychedelic fans and they will go to war for you in the worst of times.
See MindMed as an example of rabid fans. There is no such link on their websites you will click on and get zero information. The same goes for Cybin and GH Research as further examples in the psych space. Follow the path of successful companies in the growing psych sector. Thus, a complete overhaul of Algernon’s website. It would be money well spent for pending and future endeavors.
In addition, management apparently believes showing less faces, faces that would include a woman (show diversity) is not important.
Top websites that heavily rely on name and face recognition:
In addition, management apparently believes showing less faces, faces that would include a very smart woman (showing diversity) is not important to Algernon's overall image.
Personally, I believe it’s less professional and less transparent in a world where a company named Facebook|Meta|Instagram dominates the World Wide Web.
Surely, companies like GH Research and Cybin and MindMed get the big picture.
www.ghres.com/company
cybin.com/our-team/
mindmed.co/team/
The only name on the following list with a photo at Algernonpharmaceuticals.com is Christopher J. Moreau.
Christopher J. Moreau
55
2018
CEO & Director
Harold J. F. Bloomfield
77
2021
Independent Chairman of the Board
Rajpaul Attariwala
54
2015
Independent Director
Mark Williams
50
2018
Director
Martin Kolb
-
2019
Member of Medical & Scientific Advisory Board
Mark Swaim
-
2020
Member of Medical & Scientific Advisory Board
Jacky Smith
-
2020
Member of Medical & Scientific Advisory Board
Howard W. Gutman
64
2020
Director
W. Bruce Rowlands
-
2022
Member of Business Advisory Board
www.investing.com/equities/breathtec-biomedical-company-profile
Anybody recall an official announcement of this director appointment?
W. Bruce Rowlands
Algernon has appointed W. Bruce Rowlands to its Business Advisory Board. Mr. Rowlands has extensive public company experience over the last 25 years and recently was the Chairman of Xortx Therapeutics, a Canadian Biotech company focused in kidney disease on whose board he served for almost 8 years. He also served as Vice President & Director of Dominick & Dominick Securities Canada, SVP Lorus Therapeutics, now Aptose Bioscience, and Chairman & CEO Eurocontrol Technics Group Inc.
algernonpharmaceuticals.com/business-advisory-board/
Mr. W.Bruce Rowlands appears to have taken the place of Howard Gutman, Howard Gutman (Ambassador) has taken the place of David Levine (a longstanding lapdog for King Cobra going back to the disastrous days of Breathtec Biomedical).
Meanwhile, management can start with some low hanging fruit to help the cause:
algernonpharma.com - Domain name appears to be registered for sale at GoDaddy.com
Give GoDaddy hell management.
R O T F L M A O
M$
Correction:
Q&A -
Does Moreau TRULY believe there will be the start of 3 additional Phase 1 clinical trials in Q4 2022?
Chronic Kidney Disease - Phase 1 Q4 2022
Pancreatic Cancer - Phase 1 Q4 2022
Small Cell Lung Cancer - Phase 1 Q4 2022
algernonpharmaceuticals.com/wp-content/uploads/2022/03/Untitled-8-01.png
M$
I don't see much upside at their pace of performance.
Waiting for Nasdaq listing (new trading symbol).
Waiting for massive dilution - fire sale capital raise.
Waiting for the start of Phase 1 DMT since Q4 of last year's timeline.
Q&A -
Does Moreau TRULY believe there will be the start of 3 additional Phase 1 clinical trials in Q4 2020?
Chronic Kidney Disease - Phase 1 Q4 2022
Pancreatic Cancer - Phase 1 Q4 2022
Small Cell Lung Cancer - Phase 1 Q4 2022
__________________________________
My best guess is DMT Phase 1 will be the only thing going on in 2022. Moreeau will not launch additional clinical trials in 2022.
There is a lot of negativity piled up at the hands of management and its past operations.
When you look at a company like GH Research with one lone Psychedelic drug in its portfolio, you seriously have to ask how they are able to operate at such a high level of respectability?
The best guess is to simply look at the caliber/depth of their management teams.
GH Research has a seriously deep depth of Bio-pharmaceutical experience and financing experience.
Algernon had Michael Sadhra - Kal Malhi's penny stock right hand man and bean counter around pennyland.
Now Algernon has Moreau's longtime/10 year bean counter from Miraculins (James Kinley).
GH Research Board Of Directors is also Heavy on finance and pharmaceuticals background.
Algernon hired Moreau's old pal from Miraculins as the Chairman of The Board.
There's two doctors on the 5 person board. One doc has a PhD (Williams) the other doc is MD, PhD (Attariwala).
Attariwala spends his time circling the globe to talk to "World Leaders", as told by Attariwala, regarding his personal Body Scan machine.
Algernon Pharmaceuticals - 3 Million to 10 Million Market Cap on any given trading day in Pennyland.
GH Research 800 Million to 1.2 Billion Market Cap on any given trading day on Nasdaq.
There has never been any pleasant surprises coming from HQ.
It's all primarily been delays and ultimate disappointment since Christopher Moreau's tenure and the years prior.
Moreau even handed off its longstanding research in collaboration with Cannabix for not a single dime in return.
It was a one way street where Moreau drove the bus over the cliff for the FAIMS technology. What would it have cost to keep it in the wheelhouse if not for anything else than synergy from Cannabix's cult following that will pump a last leg stock back to life time and again?
it was a signal then that he didn't give a shit about shareholders investment up to the point they gutted us with the repurposed drugs angle.
Moreau is a man made by a string of businessmen who run companies like mob bosses and run them into the ground.
I truly do not view these people as being serious about anything other than selling cheap shares for quick profit - Fam/Friends/Cayman Islands/Fire Sale + Warrant Plan
Yeah...there will be lots more to talk about. All likely revolving around what they are not getting done in a timely manner.
Viva La Australia! The place you compete for small batches of clinical trial patients and clinics all in the name of tax incentives.
Incentives that are detrimental to the momentum of a stock waiting for clinical trial results the company (management) has zero control over halfway around the world.
The Australia route killed Algernon's momentum at the time it was most needed to provide clinical trial results in the back end of the flopped COVID-19 study in 2nd World country of Romania (80% of all patient enrollment).
Moreau appears to have no shame for the timeline of the IPF/CC study. He admitted as much in the news release. He was pleased with how the IPF/CC timeline was progressing.
^That's an insane position to take. Moreau can't seem to get out of the way of his own messaging. He basically endorses very egregious timeline failures.
Moreau is a highly unpredictable Drama Queen. I think he relishes in the thought of being the CEO at a company regardless of its overall accomplishments. He soon enough proved himself to be a yes-man for Kal Malhi - in spectacular fashion @ First Responder Technologies.
Kal Malhi got his pound of flesh out of those two (loyalty/kiss the ring). Moreau and Williams got their pound of flesh out of First Responder shareholders. Simply look at where First Responder Technologies is now in Pennyland.
Actions speak louder than words.
Will the low caliber of Algernon's history play a part in a potential uplist. Does Nasdaq simply look at numbers or give management/board of directors a deeper dive under the surface?
I’ve been at my wits end following this story since 2015 (pre-listing to CSE/OTC) in conversation with Kulwant Malhi (Founder).
I will remain skeptical of management ever getting itself to a respectable level of competence in the publicly traded space.
My expectations for the level of success for Algernon has been drastically decreased.
I have come to the conclusion Algernon will simply be an effective dilution machine moving forward as in the past.
Moreau has reset the Outstanding Shares to a level that surely causes him to wake up everyday thinking of how he can/will get his hands on 50 Million Dollars sitting on the Shelf Prospectus - sooner rather than later.
Surely, they are going after 10M USD at minimum in this next fire sale.
Thus, I have drastically decreased my expectations of Algernon’s ability to increase market cap/share price.
I will take heed to their In-House stock analyst - Andre Uddin @ Research Capital (see Corporate Fact Sheet).
They gave Andre Uddin his own banner on the Corporate Fact Sheet.
algernonpharmaceuticals.com/wp-content/uploads/2018/01/Corporate-Fact-Sheet-March-9-22-Int-f.pdf
Therefore, management heavily endorses Uddins analysis of Algernon Pharmaceuticals.
“Research Capital has a Speculative Buy rating and a CA$25 per share target price on Algernon Pharmaceuticals.” - Andre Uddin
We view refractory chronic cough as Algernon’s priority indication down the road and believe investors should keep a close eye on it. “ - Andre Uddin
www.streetwisereports.com/article/2022/01/31/co-focused-on-pipeline-of-drug-candidates.html
One MUST UNDERSTAND what Uddin is saying in his analysis of Algernon’s pipeline:
Uddin does not place any value on the Pancreatic Cancer Phase 1 or Small Cell Lung Cancer Phase 1, both scheduled for Q4 2022 launch.
Uddin does not place any value on the DMT (Stroke) Phase 1 or Phase 2, both scheduled back to back for Q4 2022 and Q1 2023.
Therefore, over the next 12 months according to the filed documents - Algernon will have tripped through multiple catalysts for DMT.
Management has also decided to finally take another drug off the shelf of drugs purchased from NASH Pharmaceuticals for Chronic Kidney Disease (CKD).
Uddin does not place any value on the CKD Phase 1 scheduled for Q4 2022.
THAT'S A TOTAL OF 5 CLINICAL TRIALS UDDIN DISMISSES IN HIS ANALYSIS
So what does Uddin pin his $25 CAD Market Cap claims on…The long running 20 patient data readout for Chronic Cough awaiting completion in Australia.
^That shit is pure insult to injury!
Meanwhile, the CEO continues to throw up Bellus Health as a pure comparison.
Bellus Health reached a BILLION DOLLAR MARKET CAP pending its second Phase 2 Chronic Cough results. It currently has a buy rating with a Market Cap north of 1.5 Billion.
Bellus Health released Topline results back in December 2021. They have yet to release Final Data but have already announced the start of Phase 3 in 2H 2022.
Best guess is Bellus Health will start their Phase 3 before Algernon gets its final data results maybe in Q3 2022.
Bellus Health has run circles around Algernon with two Phase 2 Chronic Cough studies and data readouts in less time it's taking Algernon to conduct 1 study for 20 patients.
I get the sheer incompetence that projects onto management at Algernon.
What I don’t get is how does Uddin completely ignore all clinical trials in 2022/2023 other than a pending data readout for IPF and CC where Uddin makes zero mention of Idiopathic Pulmonary Fibrosis and pins all of Algernon’s supposed value on a Chronic Cough study of 20 people with severe lung damage (IPF) which the CEO stated in a webinar you shouldn’t pair Chronic Cough studies with IPF patients.Yet, they did! As if the overall goal is to just make shit as hard as possible to move forward in the process.
As we all now know, the Chronic Cough study is not powered for statistical significance. Meaning, the study was never designed to move beyond Phase 2. It’s a study to study if Algernon wants to move forward with a Phase 2 clinical trial powered for statistical significance.
The Repurposed Drugs Strategy is a ruse. It doesn’t necessarily do what management continuously claimed it would do. Moreau talked endlessly about 65% chances of getting past Phase 2. Does anyone remember that? Doc Williams tripped out the same nonsense. With his mathematical formula about how it's all de-risked because we know the drug is safe.
Yeah , ok.
The Huge Problem with Doc Williams math problem is he leaves out the fact the study designs for COVID-19 and IPF/CC was never going to move the needle beyond Phase 2. Thus, whatever the outcome of the studies it’s back to Square 2.
However, starting at Phase 2 doesn’t matter now because Management has stepped back the whole process of bypassing Phase 1. All pipeline drugs slated to start in 2022 will start at Square 1/Phase 1 of the clinical trial process. We have moved backwards in the process of a “Company Reorganization” and drastic Share Consolidation.
Getting back to Andre Uddins’ CA$25 per share price target…
What Uddin is saying is his previous price target of CA$80 per share price target was all COVID-19. IPF/CC had already launched in Australia when Uddin put his analysis out to the masses.
COVID-19 Topline Data Readout (December 2020 - Merry Christmas!) from the COVID-19 study flopped miserably. Subsequently - “Along with the new “Hold” rating, Uddin has cut his price target from $0.80 to $0.25, saying the drop is due to a decrease in assumed success rate for Ifenprodil. At the time of publication, the new target represented a projected one-year return of negative 15 per cent.”
www.cantechletter.com/2021/04/take-a-pass-on-algernon-pharmaceuticals-says-mackie/#
ALgernon’s stock was trading above CA$0.30 just prior to Uddins’ analysis dropping on top of shareholders.
So in the final analysis of Uddins’ analysis, Uddin views Algernon’s prospects for the foreseeable future is driven by data from 20 patients that will justify running a real world Phase 2 clinical trial powered for statistical significance to move the needle to a phase 3.
Uddin values non-statistically significant “studies’ over statistically significant studies.
Uddin believes the DMT and Cancer angles have zero value.
Uddin completely dismisses the pending IPF data.
I believe Uddins’ analysis serves only one real purpose.
That being keeping the share price suppressed as long as possible leading up to the next capital raise.
Uddin makes absolutely no sense by concentrating solely on Chronic Cough.
Algernon doesn’t even have a timeline for moving Chronic Cough to another Phase 2 study.
Algernon has not reconciled with the fact their Australia operations are complete bullshit.
The waiting game for clinics and patients among pharmaceutical Whales in Australia should be a non-starter for running any serious clinical trial you are attempting to complete in a timeline that can make a real difference in your share price, shareholder sentiment, and management competency.
Algernon couldn’t execute its strategy in Australia and New Zealand for 20 FRIGGIN PATIENTS.
Yet, Moreau wants to go back for more of the same to save a buck that shareholders will pay back in very harsh terms for future dilution. Dilution of shares and dilution of share price. It’s a lose-lose proposition and operation in Australia.
Think of the damage still being inflicted to the company for the AU/NZ data delays. Management is still relying on the pre-clinical trial data for Algernon having smoked Merck’s Chronic Cough drug. It’s now old news that the FDA did not approve Merck’s drug (Gefapixant).
www.fiercebiotech.com/biotech/merck-s-chronic-cough-med-rejected-by-fda-accepted-japan-potentially-paving-way-for-bellus
Which is why Bellus Health appears to be the front runner for getting a Chronic Cough drug to market. Hence, Bellus Health received a $1.7 Billion price target going into the start of its Phase 3 study slated for 2H 2022.
If anyone wants to get a quick and simple gauge of how Algernon/management is doing in the eyes of real world stock analysts just hold up Bellus Health’s approach to getting to clinical trial data results versus Algernon’s approach to getting to clinical trial data results.
One thing I’ll be interested in seeing is if/when other analysts begin covering Algernon.
Uddin along with Mackie Mackie Research has slapped Algeron silly in more ways than one. Yet, Moreau wants to hang his thinking cap on numbers pumped out by Andre Uddin.
Thus, Christopher Moreau would have everyone believe Algernon’s share price was worth CAD$80 pending data from the COVID-19 study.
COVID-19 flopped.
Thus, Christopher Moreau would have everyone believe Algernon’s share price was worth CAD$25 pending data from the IPF/Chronic Cough study.
IPF/Chronic Cough data is more than a year past due.
Subsequently, Algernon added Small Cell Lung Cancer, Pancreatic Cancer, Chronic Kidney Disease, and DMT Phase 1 and 2 to the 2022 pipeline along with the pending data readout for Chronic Cough covered by Uddin.
Yet, with all the additional ammo loaded for 2022, the full-throated endorsement of Andre Uddins’ analysis would have you believe Algernon’s share price is still valued at CAD$25 per share.
Keeping in mind the price targets are reflective of pre and post consolidation of shares (100 to 1 reverse split).
CAD$0.80 is now CAD$80 = $62 USD (pre-split)
CAD$0.25 is now CAD$25 = $20 USD (post split)
Management/Uddin has placed a $20 USD ceiling on the valuation of Algernon moving forward.
That’s a $33 Million USD Market Cap for Algernon Pharmaceuticals.
At the point Algernon raises $10 Million USD, with a doubling of the current Outstanding Shares of 1,674,868, a $30 Million USD Market Cap would place the share price at $9 USD per share.
THAT’S A 9 CENT USD PRE-SPLIT SHARE PRICE !!!
F*** Management and the Jackasses they worship (Malhi/Uddin...) in Dante’s Inferno.
If anyone believes they've heard it all before...you probably have.
Suck it up for any newbies and woefully ill-informed investors.
M$
PostScript
Any Common Shareholder (investors not a party to any Private Placements) still holding pre-split shares remains in Purgatory.
Outro
www.youtube.com/watch?v=wr27-cs1rnY
Oh! If you and others (there's power in numbers) are ever able to get your management to release the Texas Forum video, brace yourself for Dr. Boock's (Lead Developer @ Cannabix Technologies Inc.) response to his phone going off 3 times throughout the presentation. College Campus pranksters no doubt Got Em!
EPIC ANTICS
Sparks Flying
LMAO
M$
Have you watched the Texas Forum presentation by Dr. Boock?
If not, you like 99% of all others are flying blind my friend.
If I recall correctly, there was less than 50 people who actually watched the live presentation by Dr. Boock.
How pathetic is that (rhetorically speaking)?
In regards to patents - less than 10% of all patents ever make any money/revenues.
Meanwhile, await another news release about more testing of a prototype device.
What's new...
M$
Get what you can while you can. It is 100% a certainty this group of characters including the characters at Algernon are in it for themselves. Period. If you ever catch me in Vegas I'll probably know where all the bodies are buried.
M$
I find it truly incredible that the masses of people who have followed Cannabix for Years - still cannot come to the conclusion that Cannabix does not have a working device for the masses. Their "prototype" remains in tinkering and testing mode for the foreseeable future. Management already forecast the next 4 years or more of the same when they brought Germany into the equation. Malhi has got to be overjoyed by a years-long pot stock crowd turned cult. The narrative for Cannabix is fast approaching the cliff. How many more tinkering and testing news releases will pump the stock like clockwork? If anything, they will come up with some other tech to peddle to the masses once the market handily rejects the nearly 8 Year prototype narrative. As I've said before, anyone who has not seen the Texas Forum with Dr. Boock is flying blind now. Dr. Boock's presentation was disastrous. Why do you think you can't get your hands on the recorded session? All the other participating companies have made their presentations available to whomever is interested. It seems as if the truth is a hard thing to swallow for all involved with Cannabix Technologies Inc.
Par for the course,
M$
No. I'm trying to find the exit.
M$
The insiders are about to run their dilution scheme through the roof. Any increase in share price is the last thing on Moreau's Mind to raising capital.
Pennyland Schemes for Millionaire Dreams.
M$
They will do a raise regardless to an uplist. However, if you think a Nasdaq uplist will happen anytime soon you should understand the capital raise comes with it. You do know what an IPO is right? There can be rants all day long about the upcoming clinical trials. The bottom line is they walked back the entire pipeline to start at pre-clinical to Phase 1. The BS story about fast tracking molecules into Phase 2 clinical trials was always BS. As I've stated before it will be years before Algernon gets to an actual Phase 2 data readout and could be a decade if Moron Moreau is hell bent on slow rolling the results by going back to Australia. Slow rolling data readouts only helps insiders accumulate more shares on our time and dime. That's been the playbook to date. They could care less about getting expedient results. They live lavish no matter what.
The latest filing spells out the timelines and cost of each clinical trial set to start in 2022. News flash: They have less than one-fifth of the money on hand needed to meet the goals as written in black and white. Hence, massive dilution (100+ % increase in outstanding shares) is coming sooner rather than later. Best guess is sub $3 is where this stock will be after Moreau's market "softening" of the share price after the next dilution scheme. Andre Muffin laid out his BS analysis of Algernon @ $20 per share/$30M market cap. The next round of shares plus warrants will be sold at a fraction of the cost.
Of note: Bellus Health received a Buy rating of $16 per share by HC Wainwright. That gives Bellus Health a $1.7 Billion valuation. They are a one trick pony with Chronic Cough. Moreau believes they are a pure comparison to Algernon. Anyone believe Bellus Health's management team is as incompetent as Algernon at executing a strategy?
M$
Hard to believe after all these years (almost 8 years) they are still talking about what they believe law enforcement needs for roadside DUID's.
A recency of use device versus a device that determines actual impairment (the true Holy Grail).
Meanwhile, in the real world...
Cannabix Technologies Inc.
Yeah...the phone going off 3 different times during the presentation and the 3rd time it sounded like Dr. Boock destroyed the phone by slamming it to the ground. I was ROTFLMAO @ that. Whomever was blowing up his phone was probably watching the presentation and laughing as well in real time. Oh those college campus folks love playing pranks. As to weather conditions, the device has never been in the hands of Law enforcement at the roadside. I would use extreme caution in believing their device can handle all weather conditions. At the end of the day, Cannabix is no closer to having a commercial ready device than they were when they pumped the device back in 2016/2017 for legalization of marijuana in Canada. The technology Cannabix is using for RECENCY OF USE is being looked at by the scientific community as inadequate technology for the challenges of DUID. There needs to be an actual determination of IMPAIRMENT by Law enforcement for a marijuana device to be accepted evidence in a court of law. Lawyers have been saying the same thing for years. What you continue to get from Cannabix is mealy mouthed concepts and narratives that simply fit the story they want to peddle to continue getting your money (see today's news release). IMO, Cannabix is toast on two levels. The first level is Hound Labs will ultimately peddle their product to the market for the lions share of whomever is willing to buy into the RECENCY OF USE angle. My guess is it will not be a significantly large market overall. I'd be shocked to see just one Law enforcement agency buying into the Hound device. Employers are a different story. That's where the initial push of Hounds product will generate revenues. As time moves forward there will be technology coming to the forefront that will detect IMPAIRMENT OF THE BRAIN through examination of actual brain function at the roadside or where ever with head wear technology. It wont be about chasing down some molecule in your body as a means to suggest someone is impaired. The whole Recency of Use angle gets more and more ridiculous as time goes bye bye. Who knows what it'll take for the potheads to wise up about Cannabix? Bottom line is the Texas Forum presentation by Dr. Boock was a disaster. Right out the gate it reminded me of a terrorist video with his dark clothes and dark and creepy background scenery. It was simply a weird thing to watch. Dr. Boock himself appeared to be the hostage forced into doing the presentation. Grade F
Peace,
M$
What catalyst is going to move the stock in any significant way BEFORE an uplist to Nasdaq? You believe cheap ass pennyland is going to push the stock up from the gutter it's been in for nearly 1 year now? Moreau and the Miraculins boys are content with more than doubling the outstanding shares at this price point. Meaning, their people can buy up more than half the company (again) at dirt cheap cost. Consolidation will prove to be a whitewash of pre-split shares. Every move they make further diminishes the value of your hold. Moreau even knows if/once the uplist takes place the stock is going to tank. He said as much when he used the phrase "A softening" after a capital raise. It's also written directly in the filing to expect a significant drop in price of IPO shares. It's all there in black and white and red all over - newspaper.
M$